Abstract 599TiP
Background
Hepatocyte growth factor receptor (HGF)/mesothelial-epithelial transition (MET) pathway activation is known as an oncogenic driver in NSCLC. MET overexpression has been reported to be associated with worse clinical outcomes of NSCLCs. In China, the current second-line standard of care for EGFR/ALK/ROS1/METex14m-wildtype NSCLC with MET overexpression is mono-chemotherapy or immune checkpoint inhibitor, but with limited efficacy. Preclinically, the synergistic effect of savolitinib and docetaxel was tested in both CDX and PDX models. A phase I study explored the safety and tolerability of savolitinb plus docetaxel in advanced solid tumors. This study (NCT05777278) aims to explore the efficacy and safety of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression.
Trial design
This is an ongoing, phase I/II, pilot, open-label, single arm, single center, interventional study. Eligible patients will be those diagnosed with MET overexpression, EGFR/ALK/ROS1/METex14m-wildtype NSCLC in advanced stages and not treated with MET inhibitors. MET overexpression is defined as IHC 3+ in ≥50% of tumor cells. Patients will receive docetaxel (60 mg/m2, ivgtt, q3w) and savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID) after signing informed consent. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, other discontinuation criterion is met, or study completion. The primary objectives include assessing the efficacy by Objective Response Rate (ORR) and the safety and tolerability profile of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression. The secondary objective is to assess the efficacy through Progression-Free Survival (PFS), Duration of Response (DoR), Disease Control Rate (DCR), Overall Survival (OS), 12 months OS rate using investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The exploratory objective is to assess efficacy in the MET-high (in 90% tumor cells IHC 3+) population.
Clinical trial identification
NCT05777278, 03/17/2023.
Legal entity responsible for the study
The authors.
Funding
AstraZeneca, China and Hutchison Whampoa, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract